Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
Agilent Invests In Synthetic Bio Firm
by Ann M. Thayer
May 6, 2013
| A version of this story appeared in
Volume 91, Issue 18
Agilent Technologies has invested $21 million and gained an equity stake in Gen9, a Cambridge, Mass.-based synthetic biology company. Gen9 will use the money to advance product development and expand its infrastructure for commercial-scale gene synthesis. Gen9 will also gain access to Agilent’s oligonucleotide library synthesis technology for making DNA libraries and pathway constructs. Researchers from MIT, Harvard Medical School, and Stanford University founded Gen9 in 2009.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter